Amgen Inc (NASDAQ:AMGN) – Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer

[at noodls] – Whippany, NJ and South San Francisco, CA . – Jul 25, 2014 Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary (NASDAQ:AMGN), today announced that an investigational Phase 3 trial . . . → Read More: Amgen Inc (NASDAQ:AMGN) – Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer Similar Articles: Company Update: Pfizer Inc (NYSE:PFE) – Pfizer’s new breast cancer drug succeeds in trial Merck & Co. Inc. (NYSE:MRK) – 8:31 am Merck initiates rolling submission of U.S. Biologics License Application for MK-3475, an investigational Anti-PD-1 Immunotherapy, in patients with advanced melanoma; expects to complete application in 1H14 AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.